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Abstract
Background: Tegaserod is effective in treating IBS patients with constipation, and does not alter
gallbladder motility in healthy individuals or in patients with IBS. However, it is not known if
tegaserod affects the biliary tract in gallstone disease, so to this end the effects of tegaserod on bile
composition and hepatic secretion of Richardson ground squirrels maintained on an enriched
cholesterol diet were examined.
Results: Animals were fed either a control (0.03%) or enriched (1%) cholesterol diet for 28 days,
and treated s.c. with tegaserod (0.1 mg/kg BID) or vehicle. Bile flow, bile acid, phospholipids and
cholesterol secretion were measured with standard methods. Tegaserod treatment or enriched
cholesterol diet, alone or combination, did not alter body or liver weights. The enriched
cholesterol diet increased cholesterol saturation index (CSI), cholesterol concentrations in
gallbladder and hepatic duct bile by ~50% and decreased bile acids in gallbladder bile by 17%.
Tegaserod treatment reversed these cholesterol-induced changes. None of the treatments, drug
or diet, altered fasting gallbladder volume, bile flow and bile salts or phospholipid secretion in
normal diet and cholesterol-fed animals. However, tegaserod treatment prevented the decreases
in bile acid pool size and cycling frequency caused by the enriched cholesterol diet, consequent to
re-establishing normal bile acid to concentrations in the gall bladder. Tegaserod had no effect on
these parameters with normal diet animals.
Conclusion:  Tegaserod treatment results in increased enterohepatic cycling and lowers
cholesterol saturation in the bile of cholesterol-fed animals. These effects would decrease
conditions favorable to cholesterol gallstone formation.
Background
Irritable bowel syndrome (IBS) is a poorly understood
symptom complex with abdominal pain and altered
bowel function. Its basis likely involves visceral hypersen-
sitivity and altered intestinal motility, perhaps mediated
by the serotonin (5-HT) receptors [1]. IBS is not merely a
motility disorder confined to the colon, but may involve
the entire gut, urinary tract and gallbladder. As to the
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involvement of gallbladder in IBS, the reports have been
conflicting. A small percentage of patients with IBS may
have gallbladder disease[2], and some studies have shown
normal[3,4], others enhanced[5], or impaired [6]gall-
bladder emptying in IBS. Despite these contradictions
there is a higher rate of cholecystectomy in patients with
IBS than that predicted in the general population[5,7].
One of the drugs being used for IBS that influences gut
motility is tegaserod. Tegaserod, initially identified as a 5-
HT4 partial agonist[8] and subsequently shown to antago-
nize 5-HT2B receptors[9] increases intestinal transit[10]
and affects visceral afferent function by blunting the
somatic reflex to colonic distension[11]. Consequent to
these effects on colonic motor and sensory function,
tegaserod is indicated for the treatment of irritable bowel
syndrome with constipation in women (reviewed in[12]).
Although functional 5-HT4 receptors have not been dem-
onstrated in the gallbladder or biliary tract, cisapride, a 5-
HT4-agonist/5-HT3-antagonist, has been variably reported
to increase, decrease, and have no effect on gallbladder
volume in human subjects[13-15]. Our previous
work[16] with cisapride, in the Richardson ground squir-
rel model of cholesterol gallstone formation, revealed that
this prokinetic agent reversed the defect in gallbladder
contractility, enhanced bile salt secretion and so lowered
cholesterol saturation. This increased hepatic bile salt
secretion despite a reduction in the bile salt pool size, low-
ered the cholesterol saturation of bile, and reduced crystal
nucleation and stone formation. Studies on the effect of
tegaserod on hepatobiliary function are limited, although
recently this drug was shown to have no significant effect
on gallbladder contractility or the diameter of the com-
mon bile and hepatic ducts during both the interdigestive
(fasting) and the digestive (postprandial) periods in
healthy female subjects and female patients with IBS[17].
Thus, the objective of this study was to assess the effects of
tegaserod on the enterohepatic circulation in a well-estab-
lished animal model of gallbladder disease, the Richard-
son ground squirrel.
Results
Animal health
All animals remained in good health over the duration of
the study, and tolerated the diets and daily interventions.
There were no significant changes in initial and final body
weights or the weights of the liver between the four groups
of treatment animals (Table 1).
Gallbladder lipid composition (Figure 1)
After an overnight fast cholesterol-fed, vehicle-treated
(VC) animals had a higher concentration of cholesterol in
gallbladder bile relative to normal diet animals (VN). In
addition, gallbladder bile of the VC animals had a signifi-
cantly lower concentration of bile acids relative to VN.
These changes translated into a higher CSI in VC gallblad-
der bile than with VN. Tegaserod treatment did not mod-
ify the composition of gallbladder bile in animals on a
normal diet (TN), but prevented the TC-induced changes
in bile acids and cholesterol so that CSI was normalized
to the values measured in VN.
Hepatic duct bile lipid composition (Figure 2)
Relative to VN the concentrations of bile acids and choles-
terol in hepatic duct bile of VC were increased, although
phospholipids were not affected. CSI was thus increased
in VC. Tegaserod (TC) reversed these increased. With TN a
small decrease in hepatic bile acid concentration
occurred, but phospholipids and cholesterol concentra-
tions remained unchanged relative to VN.
Biliary lipid secretion rates, pool size and cycling time 
(Figure 3)
Hepatic bile flow and the secretion rates for bile acids and
phospholipids were the same for the four treatment
groups. The ~100% increase in cholesterol secretion that
occurred with VC was reversed in TC. A reduction of bile
acid pool size occurred in VC, due to the lower concentra-
tions of bile acids in the gallbladder, and thus the cycling
rate of the bile acid pool was decreased. Tegaserod treat-
ment re-established pool size and normal cycling rate in
TC, but did not modify cycling frequency in TN.
Table 1: Animal Characteristics
Normal Diet 1% Cholesterol Diet
Vehicle Tegaserod Vehicle Tegaserod
Initial Body Weight (g) 558 ± 15 541 ± 12 508 ± 24 523 ± 27
Final Body Weight (g) 537 ± 13 535 ± 26 517 ± 24 503 ± 23
Liver Weight (g) 12.8 ± 1.1 12.5 ± 0.9 12.1 ± 0.8 11.8 ± 0.4
Gallbladder Weight (mg) 23.6 ± 1.4 24.8 ± 2.2 22.6 ± 1.5 23.6 ± 1.2Lipids in Health and Disease 2006, 5:15 http://www.lipidworld.com/content/5/1/15
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Discussion
The Richardson ground squirrel fed a cholesterol-enriched
diet serves as a model of gallstone disease[16,18-20], as
this animal model exhibits impaired gallbladder contrac-
tility and increased cholesterol saturation index and cho-
lesterol secretion, and decreased secretion of bile acids;
the classical conditions favoring the formation of gall-
stones in obese humans[21,22]. The results of the current
study concord with these previous observations in that the
cholesterol-enriched diet increased CSI, decreased gall-
bladder bile acids concentrations, and enhanced choles-
terol secretion and accumulation in gallbladder bile
(Figure 1), but did not influence bile flow[23,24]. These
conditions would favor lithogenesis. Although the previ-
ously reported[19,20] decrease bile acid secretion with VC
animals was not observed in the present study, the con-
centrations of bile acids in the gallbladder were signifi-
cantly reduced (Figure 1), and overall an increase in
cholesterol concentrations in both gallbladder and
hepatic bile, and a decrease in gallbladder bile acids, con-
tributed predominately to an increase in CSI characteristic
of an enriched cholesterol diet[16,18-20].
Tegaserod, a prokinetic agent[25] is associated with
improved bile composition as reflected in an improved
enterohepatic circulation (Figure 3). This result contrasts
with the improved bile acid secretion and negligible
effects on cholesterol secretion seen with another proki-
netic agent cisapride[16], but concords with reduced cho-
lesterol concentrations and CSI in patients with gallstone
disease treated with cisapride[26]. The cholesterol lower-
ing effects of cisapride has been attributed to enhanced
bile salt secretion[16], but since bile acid secretion was
not increased in TC animals, an alternative mechanism
must be responsible for the cholesterol-lowering effects of
tegaserod. Two possible inter-related mechanisms may
explain this corrective action of tegaserod.
Ground squirrels fed a VC diet had a prolonged migrating
myoelectric complex cycle (MMC) period[20], increased
cholinergic contractions of intestinal smooth muscle[27]
and impaired enterohepatic cycling[20] (Figure 3). The
improvement of enterohepatic circulation could occur in
TC animals consequent to increased gastrointestinal tran-
sit[28], with resulting normalization of the cholesterol
composition of hepatic duct bile (Figure 2). The increased
cholinergic contractions in VC animals, which could dis-
rupt MMCs[29], may arise from cholesterol metabolites
Biliary lipid concentrations and cholesterol saturation index  for hepatic duct bile Figure 2
Biliary lipid concentrations and cholesterol satura-
tion index for hepatic duct bile. Bile acids, phospholipids, 
cholesterol concentrations (nmol/l) and cholesterol satura-
tion index (CSI %) were measured in four groups of animals: 
VN = vehicle + normal diet (n = 15), VC = vehicle + choles-
terol diet (n = 15), TN = tegaserod + normal diet (n = 16), 
and TC = tegaserod + cholesterol diet (n = 17). Significance 
(P < 0.05): * less than VC; ** greater than TN; # less than 
VN; ## greater than VN.
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Biliary lipid concentrations and cholesterol saturation index  for gallbladder bile Figure 1
Biliary lipid concentrations and cholesterol satura-
tion index for gallbladder bile. Bile acids, phospholipids, 
cholesterol concentrations (nmol/l) and cholesterol satura-
tion index (CSI %) were measured in four groups of animals: 
VN = vehicle + normal diet (n = 17), VC = vehicle + choles-
terol diet (n = 15), TN = tegaserod + normal diet (n = 15), 
and TC = tegaserod + cholesterol diet (n = 17). Significance 
(P < 0.05): * less than VC; # less than VN; ## greater than 
VN.
Bile Acids
VN VC TN TC
0
50
100
150
200
250
#
n
m
o
l
/
l
Phospholipids
VN VC TN TC
0
5
10
15
20
25
n
m
o
l
/
l
Cholesterol
VN VC TN TC
0
1
2
3
4
5
6
7
##
n
m
o
l
/
l
Saturation Index
VN VC TN TC
0
20
40
60
80
100
##
*
C
S
I
 
%
Gallbladder BileLipids in Health and Disease 2006, 5:15 http://www.lipidworld.com/content/5/1/15
Page 4 of 7
(page number not for citation purposes)
Hepatic flow rates, pool size and cycling frequency Figure 3
Hepatic flow rates, pool size and cycling frequency. Hepatic bile flow rate (μl/hr/kg), flow rates (μmol/hr/kg) for bile 
acids, phospholipids, cholesterol, pool size (μmol/kg) and cycling frequency (cycles/24 h) were measured in four groups of ani-
mals: VN = vehicle + normal diet (n = 14), VC = vehicle + cholesterol diet (n = 11), TN = tegaserod + normal diet (n = 16), 
and TC = tegaserod + cholesterol diet (n = 16). Significance (P < 0.05): * less than VC; ** greater than VC; # less than VN; ## 
greater than VN.
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blocking inhibitory neuronal muscarinic recep-
tors.[27,30]
Conclusion
Tegaserod, a prokinetic agent used to treat IBS in women,
increased enterohepatic cycling and lowers cholesterol
saturation in the bile of cholesterol-fed animals. Thus,
tegaserod treatment may decrease conditions favorable to
cholesterol gallstone formation.
Methods
Experimental animals
The University of Calgary Animal Care Committee
approved the researchprotocol, which conforms to the
guidelines of the Canadian Council on Animal Care.
Eighty Male Richardson ground squirrels (Spermophilus
richardsoni) were trapped wild near Calgary, and acclima-
tized for a minimum period of four weeks by caging them
individually in thermoregulated rooms on a 12 h/12 h
day/night light cycle with free access to a standard rat
chow diet. After acclimatization the animals were fed,
under the same holding conditions for four weeks, either
a normal (control) diet with trace cholesterol content
(0.027%, Dyets Inc., Bethlehem, PA) or an enriched cho-
lesterol diet (Dyets Inc.) comprising an identical chow,
enriched with 1% cholesterol by weight. During this diet
period the animals were treated subcutaneously, twice
daily, with either vehicle or 0.1 mg/kg of tegaserod. Tegas-
erod was dissolved in vehicle (100% 1-methyl-2-pyrrolid-
inone) immediately before use, and then diluted into
0.9% saline such that the final concentration of 1-methyl-
2-pyrrolidinone was 2.7%. The vehicle-treated animals
received 0.9% saline containing 2.7% 1-methyl-2-pyrro-
lidinone Sigma-Aldrich, St. Louis, MO). The animals were
randomly divided into four groups (20 in each) that
received the following combination of diet and drug: (1)
vehicle + normal diet (VN), (2) vehicle + cholesterol diet
(VC), (3) tegaserod + normal diet (TN), and (4) tegaserod
+ cholesterol diet (TC).
Hepatic secretion and bile salt kinetics
Acute terminal experiments in  vivo meanwhile directly
measured bile output, biliary lipid secretion and bile com-
position, and determine the bile salt pool size by isotope
dilution. Fourteen hours before the acute terminal studies
each animal was lightly and briefly sedated with haloth-
ane (Ayerst Laboratories, Montreal, Canada) and 0.2 μCi
of tritiated taurocholic acid, (PerkinElmer Life and Analyt-
ical Sciences, Inc., Boston, MA) was injected directly by
cardiac puncture. Animals were ambulatory within 5 min-
utes.
After a 14-hour overnight fast, animals were anesthetized
with isoflurane (BioMeda MTC, Cambridge, Ontario) and
maintained on a low concentration (1.5 to 2%) isoflu-
rane. At laparotomy the cystic duct was exposed and
ligated, the gallbladder removed and the common bile
duct cannulated with a polyethylene catheter (PE50).
Hepatic bile was collected into tared tubes on an hourly
basis for a total of 2 hours and frozen at -70°C for later
analysis. During this period, 154 mmol/L NaC1 was
infused continuously at 2.5 mL/h via a femoral venous
cannula for fluid replacement. Terminally, the liver was
wet weighed. Gallbladder bile was aspirated and the vol-
ume measured, before storage at -70°C for later analysis.
Assay of bile lipids
Bile acids were analyzed using the 3-α hydroxysteroid
dehydrogenase colorimetric assay[31] as developed into
Total Bile Acid Test Kit (enzyme cycling) by Diazyme (San
Diego, CA). This assay has linear range of 1–180 μM. Total
cholesterol (cholesterol and cholesteryl ester) was meas-
ured using a method based on the Liebermann-Burchard
reaction[32], and as developed into a Cholesterol/Choles-
teryl Ester Quantitation Kit of Biovision (Mountain View,
CA). Phospholipids were measured as total biliary phos-
phate after hydrolysis with sulphuric acid, using a modifi-
cation (Chen et al, 1965) of the colorimetric assay of Fiske
& Subbarow[33]. The results are expressed as micromole
of total bile acids per liter.
Calculations and statistical analysis
The relative lipid biliary composition, calculated after the
method of[22], was expressed as percentage molar com-
position. The CSI of each sample was calculated in native
bile using Carey's critical tables[34,35] for cholesterol sol-
ubility limits based on total lipid concentration. Biliary
secretion rate, calculated by multiplying the bile flow
(microliters per hour per kilogram body weight) with the
solute concentration (millimolar) in fraction of solute
collected over a 1 h period, was expressed as nmol·h-1·kg
body weight-1. The bile acid pool size was calculated using
a modified isotope dilution technique[16,36]. Cycling
time, defined as the time it takes bile acids to circulate
once in the enterohepatic circulation, was calculated by
dividing the bile acid pool size (micromoles·kg body
weight-1) by the bile acid secretion rate (micromoles·h-
1·kg body weight-1).
The results are presented as the mean ± SEM. The Z-test
was used to identify and exclude outliers that were more
than 3 SD from the mean. The statistical functions associ-
ated with Excel (Microsoft Office XP, Redmond, WA) were
used. Comparisons between two groups were made using
the unpaired Student's t-test, and where appropriate anal-
ysis of variance was applied. Statistical values reaching
probabilities of p < 0.05 were considered significant.Lipids in Health and Disease 2006, 5:15 http://www.lipidworld.com/content/5/1/15
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